Download PDF
Diabetologie und Stoffwechsel 2011; 6(1): 48-54
DOI: 10.1055/s-0030-1262763
Originalarbeit

© Georg Thieme Verlag KG Stuttgart ˙ New York

Verschiebung des Verhältnisses von Inflammationsmarkern in einem Kollektiv mit polyzystischem Ovariensyndrom (PCOS)

Shift in the Relation of Inflammatory Markers in a Collective with Polycystic Ovary Syndrome (PCOS)B. Knebel1 , S. Lehr1 , O. E. Janssen2 , S. Hahn3 , U. Nitzgen1 , S. Jacob1 , J. Haas4 , D. Müller-Wieland4 , J. Kotzka1
  • 1Institut für Klinische Biochemie und Pathobiochemie, Deutsches Diabetes Zentrum, Leibnitz Zentrum für Diabetes Forschung an der Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Deutschland
  • 2Endokrinologikum Hamburg, 22767 Hamburg, Deutschland
  • 3Praxis für Endokrinologie, 42103 Wuppertal, Deutschland
  • 4Institut für Diabetes-Forschung, Abteilung für Allgemeine Innere Medizin, Asklepios Klinik St. Georg, 20099 Hamburg, Deutschland
Further Information

Publication History

Publication Date:
11 February 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Patientinnen mit polyzystischem Ovariensyndrom (PCOS) weisen neben Reproduktionsstörungen Symptome des metabolischen Syndroms wie erhöhtes kardiovaskuläres Risiko und Adipositas auf. Eine akute Zunahme der Fettzellmasse infolge einer Adipositas geht mit einer vermehrten Inflammation durch den Anstieg von proinflammatorischen Zytokinen einher. Zytokine des Typs 1 und Typs 2 sowie Proinflammationsmarker wurden in einem Kollektiv von 58 PCOS-Patienten und 133 Alters- und BMI-angepassten Kontrollen mittels Multiplex-Immunoassay bestimmt. Typ-1-Zytokine IL2 und IL12 wiesen im Gegensatz zu INFγ; im Serum der PCOS-Patienten und Kontrollen keine signifikante Veränderung auf. Allerdings waren die Typ-2-Zytokine IL4, IL5 oder IL10 und die Proinflammationsmarker IL6, TNFα oder IL1β bei den PCOS-Patienten signifikant erhöht. Zieht man die Relation der Typ-1-Zytokine IL2 und IL12 zu Typ-2-Zytokinen IL1β, IL5, IL10 in Betracht, konnte bei den PCOS-Patientinnen eine drastische Reduktion dieses Quotienten beobachtet werden. Dies wurde, wenn auch mit einem geringeren Faktor für IL4 und IL6 ermittelt. Die für PCOS spezifischen Relationen zu INFγ fokussieren sich auf IL7, IL8 und IL1β aber auch auf IL5. Die vorliegende Untersuchung des PCOS-Kollektivs zeigt, dass das Sezernierungsmuster und besonders das Verhältnis von Zytokinen ein Spezifikum für PCOS ist und somit möglicherweise hieraus eine prädiktive Funktion abgeleitet werden kann. 

Abstract

Patients with polycystic ovary syndrome (PCOS) suffer next to reproductive disturbances from symptoms of the metabolic syndrome like elevated coronary risk and obesity. An increase in fat cell mass as consequence of obesity is associated with an increase of inflammation by elevation of proinflammatory cytokines. Type 1 and type 2 cytokines as well as proinflammatory markers were investigated in a collective of 58 PCOS patients and 133 age and BMI matched controls by a multiplex immuno-assay. Type 1 cytokines IL2 and IL12 in contrast to INFγ did not significantly alter in serum of PCOS patients compared to controls. Type 2 cytokines like IL4, IL5 or IL10 and the proinflammatory markers IL6, TNFα or IL1β were elevated in PCOS patients. Considering the relation of type 1 cytokine IL2 and IL12 to type 2 cytokines especially IL5, IL10 and IL1β, indicated that the quotient was drastically reduced in PCOS patients. This holds also true for IL4 and IL6 but to a lower degree. The relation to INFγ reveals a different, nevertheless PCOS specific picture, focusing on IL7, IL8, IL1γ and IL5. The study presented indicates that the pattern and especially the relation of cytokine sezernation are specific and might be useful as a predictive to PCOS. 

Schlüsselwörter

PCOS - Inflammation - Typ-1- / Typ-2-Zytokine - Th1- / Th2-System - Adipositas

Key words

PCOS - inflammation - type 1 / type 2 cytokine - th1 / th2 balance - obesity

Literatur

  • 1 Salesi M, Bravo-Vera R, Sheikh A et al. Pathogenesis of the polycystic ovary syndrome: What is the role of obesity?.  Metabolism. 2004;  53 358-376
    CrossrefGoogle Scholar
  • 2 Venkatesan A M, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes.  Recent Prog Horm Res. 2001;  56 295-308
    CrossrefGoogle Scholar
  • 3 Azziz R. PCOS: A diagnostic challenge.  Reprod Biomed Online. 2004;  8 644-648
    CrossrefGoogle Scholar
  • 4 O'Meara N M, Blackman J D, Ehrmann D A et al. Defects in beta-cell function in functional ovarian hyperandrogenism.  J Clin Endocrinol Metab. 1993;  76 1241-1247
    CrossrefGoogle Scholar
  • 5 Hudecova M, Holte J, Olovsson M et al. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve.  Hum Reprod. 2009;  24 1176-1183
    CrossrefGoogle Scholar
  • 6 Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX?.  Trends Endocrinol Metab. 2003;  14 365-370
    CrossrefGoogle Scholar
  • 7 Rebuffé-Scrive M, Cullberg G, Lundberg P A et al. Anthropometric variables and metabolism in polycystic ovarian disease.  Horm Metab Res. 1989;  21 391-397
    Article in Thieme ConnectGoogle Scholar
  • 8 Rajkhowa M, Neary R H, Kumpatla P et al. Altered Composition of High Density Lipoproteins in Women with the Polycystic Ovary Syndrome.  The Journal of Clinical Endocrinology & Metabolism. 1997;  82 3389-3394
    CrossrefGoogle Scholar
  • 9 Cinti S, Mitchell G, Barbatelli G et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.  J Lipid Res. 2005;  46 2347-2355
    CrossrefPubMedGoogle Scholar
  • 10 Kidd P. Th1 / Th2 balance: the hypothesis, its limitations, and implications for health and disease.  Altern Med Rev. 2003;  8 223-246
    Google Scholar
  • 11 Singh V K, Mehrotra S, Agarwal S S. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy.  Immunol Res. 1999;  20 147-161
    CrossrefGoogle Scholar
  • 12 Jäger A, Kuchroo V K. Effector and Regulatory T-cell Subsets in Autoimmunity and Tissue Inflammation.  Scand J Immunol. 2010;  72 173-184
    CrossrefGoogle Scholar
  • 13 Moser M, Murphy K M. Dendritic cell regulation of TH1-TH2 development.  Nat Immunol. 2000;  1 199-205
    CrossrefGoogle Scholar
  • 14 Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity.  Nat Rev Immunol. 2003;  3 133-146
    CrossrefGoogle Scholar
  • 15 Gonzalez F, Thusu K, Abdel-Rahman E et al. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.  Metabolism. 1999;  48 437-441
    CrossrefGoogle Scholar
  • 16 Kelly C C, Lyall H, Petrie J R et al. Low grade chronic inflammation in women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2001;  86 2453-2455
    CrossrefGoogle Scholar
  • 17 Escobar-Morreale H F, Villuendas G, Botella-Carretero J I et al. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.  Diabetologia. 2003;  46 625-633
    Google Scholar
  • 18 Mohlig M, Spranger J, Osterhoff M et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation.  Eur J Endocrinol. 2004;  150 525-532
    CrossrefGoogle Scholar
  • 19 Puder J J, Varga S, Kraenzlin M et al. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance.  J Clin Endocrinol Metab. 2005;  90 6014-6021
    CrossrefGoogle Scholar
  • 20 Hahn S, Fingerhut A, Khomtsiv U et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome.  Clin Endocrinol (Oxf).. 2005;  62 573-579
    CrossrefGoogle Scholar
  • 21 Song Y, Simonyi K, Thomas R et al. Simultaneous quantitation of 5 phosphorylated proteins using the Bio-Plex Protein Array System.  Bio-Rad Bull. 2000;  2632
    Google Scholar
  • 22 Kellar K L, Iannone M A. Multiplexed microsphere-based flow cytometric assays.  Exp Hematol. 2002;  30 1227-1237
    CrossrefGoogle Scholar
  • 23 Knebel B, Janssen O E, Hahn S et al. Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants.  Exp Clin Endocrinol Diabetes. 2008;  116 481-486
    Article in Thieme ConnectGoogle Scholar
  • 24 Fain J N. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells.  Vitam Horm. 2006;  74 443-477
    PubMedGoogle Scholar
  • 25 Wong H L, Pfeiffer R M, Fears T R et al. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons.  Cancer Epidemiol Biomarkers Prev. 2008;  17 3450-3456
    CrossrefGoogle Scholar
  • 26 Karadeniz M, Erdogan M, Zengi A et al. Polymorphism of the interleukin-10 gene in polycystic ovary syndrome.  Int J Immunogenet. 2008;  35 119-123
    CrossrefGoogle Scholar
  • 27 Benson S, Janssen O E, Hahn S et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome.  Brain Behav Immun. 2008;  22 177-184
    CrossrefGoogle Scholar
  • 28 Hoffman W H, Burek C L, Waller J L et al. Cytokine response to diabetic ketoacidosis and its treatment.  Clin Immunol. 2003;  108 175-181
    CrossrefGoogle Scholar
  • 29 Zozulinska D, Majchrzak A, Sobieska M et al. Serum interleukin-8 level is increased in diabetic patients.  Diabetologia. 1999;  42 117-118
    CrossrefGoogle Scholar
  • 30 Fontana L, Eagon J C, Colonna M et al. Impaired mononuclear cell immune function in extreme obesity is corrected by weight loss.  Rejuvenation Res. 2007;  10 41-46
    CrossrefGoogle Scholar
  • 31 DeLeón-Navaa M A, Navaa K, Soldevilaa G et al. Immune sexual dimorphism: Effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation.  The Journal of Steroid Biochemistry and Molecular Biology. 2009;  113 57-64
    CrossrefGoogle Scholar
  • 32 González D A, Díaz B B, Rodríguez Pérez M del C et al. Sex hormones and autoimmunity.  Immunol Lett. 2010;  133 6-13
    CrossrefGoogle Scholar
  • 33 Schneider C P, Schwacha M G, Samy T S et al. Androgen-mediated modulation of macrophage function after trauma-hemorrhage: central role of 5alpha-dihydrotestosterone.  J Appl Physiol. 2003;  95 104-112
    Google Scholar
  • 34 Escobar-Morreale H F. Polycystic ovary syndrome: treatment strategies and management.  Expert Opin Pharmacother. 2008;  9 2995-3008
    CrossrefPubMedGoogle Scholar
  • 35 Luque-Ramírez M, Escobar-Morreale H F. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.  Horm Metab Res. 2010;  42 815-820
    Article in Thieme ConnectGoogle Scholar
  • 36 Daugherty A, Rateri D L. T lymphocytes in atherosclerosis. The Yin-Yang of Th1 and Th2 influence on lesion formation.  Circ Res. 2002;  90 1039-1040
    CrossrefGoogle Scholar
  • 37 Laurat E, Poirier B, Tupin E et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice.  Circulation. 2001;  104 197-202
    Google Scholar
  • 38 Pinderski L J, Fischbein M P, Subbanagounder G et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes.  Circ Res. 2002;  90 1064-1071
    CrossrefGoogle Scholar
  • 39 Fisman E Z, Adler Y, Tenenbaum A. Biomarkers in cardiovascular diabetology: interleukins and matrixins.  Adv Cardiol. 2008;  45 44-64
    Google Scholar
  • 40 Čerkienė Z, Eidukaitė A, Usonienė A. Immune factors in human embryo culture and their significance.  Medicina (Kaunas). 2010;  46 233-239
    Google Scholar
  • 41 Saito S, Nakashima A, Shima T et al. Th1 / Th2 / Th17 and Regulatory T-Cell Paradigm in Pregnancy.  American Journal of Reproductive Immunology. 2010;  63 601-610
    CrossrefGoogle Scholar
  • 42 Koh K K, Han S H, Quon M J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.  J Am Coll Cardiol. 2005;  46 1978-1985
    CrossrefPubMedGoogle Scholar
  • 43 Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-1β contributes to glucotoxicity in human pancreatic islets.  J Clin Invest. 2002;  110 851-860
    Google Scholar
  • 44 Mueller R, Lee M S, Sawyer S P et al. Transgenic expression of interleukin 10 in the pancreas renders resistant mice susceptible to low dose streptozotocin-induced diabetes.  J Autoimmun. 1996;  9 151-158
    CrossrefGoogle Scholar
  • 45 Gallinelli A, Ciaccio I, Giannella L et al. Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic ovary syndrome.  Fertil Steril. 2003;  79 1365-1372
    CrossrefGoogle Scholar
  • 46 Szelachowska M, Kretowski A, Kinalska I. Decreased in vitro IL-4 and IL-10 production by peripheral blood in first degree relatives at high risk of diabetes type-I.  Horm Metab Res. 1998;  30 526-530
    Article in Thieme ConnectGoogle Scholar
  • 47 Rabinovitch A, Suarez-Pinzon W L. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes.  Cell Biochem Biophys. 2007;  48 159-163
    CrossrefGoogle Scholar
  • 48 Daugherty A, Rateri D L, King V L. IL-5 links adaptive and natural immunity in reducing atherosclerotic disease.  J Clin Invest. 2004;  114 317-319
    Google Scholar
  • 49 Weitzmann M N, Roggia C, Toraldo G et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.  J Clin Invest. 2002;  110 1643-1650
    Google Scholar

Dr. rer. nat. J. Kotzka

Institut für Klinische Biochemie und Pathobiochemie · Deutsches Diabetes Zentrum · Leibnitz Zentrum für Diabetes Forschung an der Heinrich-Heine-Universität Düsseldorf

Auf’m Hennekamp 65

40225 Düsseldorf

Deutschland

Email: jkotzka@ddz.uni-duesseldorf.de